Jiang Zhong Pharmaceutical Co.,Ltd: history, ownership, mission, how it works & makes money

From its roots in Nanchang as a regional drugmaker founded in 1996 to a publicly traded pharmaceutical force (Shanghai ticker 600750) since 2001, Jiang Zhong Pharmaceutical has grown into a diversified manufacturer of OTC medicines, traditional Chinese remedies and prescription drugs that reported revenue of 4.44 billion yuan in 2024 (down 2.59%) while delivering a resilient net profit of 784.9 million yuan (up 9.2%), driven by a nationwide distribution network spanning more than 5,000 pharmacies, e‑commerce channels that once contributed about 25% of sales, and a consistent R&D commitment of roughly 10% of annual revenue; strategic backing from China Resources Pharmaceutical Group (holding ~43.10% equity via its subsidiary and an effective ~26.10% interest) supports scale and collaboration as the company-with certifications like ISO9001/14001 and GMP, a market capitalization near 15.29 billion yuan (Dec 15, 2025), a trailing P/E of 16.92 and forward P/E of 17.47-posts continuing profitability (H1 2025 net profit ~522 million yuan, +5.8% YoY) while balancing sustainability, ethics and product diversification to expand its role in China's healthcare market

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS): Intro

• 1996: Company established in Nanchang, Jiangxi.
• 2001: Listed on Shanghai Stock Exchange (600750.SS).
• 2000s-2010s: Expanded product lines to include TCM, chemical medicines, and health consumer products.
• 2020s: Continued focus on branded OTC products and downstream consumer health channels.

• Publicly traded entity with free float and institutional investors on SSE; major shareholders typically include state-owned or state-related investment vehicles and strategic pharmaceutical investors (shareholder composition varies by reporting period).
• Group structure integrates manufacturing, R&D, distribution, and downstream consumer health brands.
• Governance follows PRC listed company rules with board of directors, supervisory board, and executive management responsible for operational execution and compliance.

• Mission: Provide accessible, quality pharmaceuticals and consumer health products grounded in both modern clinical formulations and traditional Chinese medicine.
• Strategic priorities: strengthen branded OTC portfolio, expand TCM product lines, invest in R&D for new formulations, optimize manufacturing efficiency, and deepen distribution in retail pharmacies and e-commerce channels.

• R&D: in-house formulation development across chemical drugs and TCM, registration dossiers for regulatory approval.
• Manufacturing: GMP-compliant production facilities for finished dosage forms (tablets, capsules, granules, topical preparations).
• Regulatory: product registration, pharmacovigilance, quality control and adherence to NMPA standards.
• Distribution & sales: national sales force, partnerships with drug distributors, retail pharmacy network, and growing e-commerce/channel presence.
• Branding & consumer health: marketing of OTC and health supplement brands to build recurring sales and shelf presence.

• 2024 revenue of 4.44 billion yuan represented a 2.59% decline year-over-year, reflecting pricing pressure, channel shifts, or product mix changes.
• Net profit improved to 784.9 million yuan in 2024 (up 9.2% YoY), indicating cost control, higher-margin product mix, or non-operating gains.
• Focus on OTC brand strengthening and channels (pharmacy chains, e-commerce) helped sustain profitability despite revenue contraction.

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS): History

• Major strategic investor: China Resources Pharmaceutical Group Limited, via China Resources Jiangzhong Pharmaceutical Group Co., Ltd, holds ~43.10% equity in Jiang Zhong as of March 2025.
• Effective control: That stake translates to an effective interest of ~26.10% for China Resources Pharmaceutical Group, leading to Jiang Zhong being accounted for as a subsidiary of the larger group.
• Public float and market presence: The remainder of shares trade publicly on the Shanghai Stock Exchange; market capitalization was approximately ¥15.29 billion as of December 15, 2025.
• Stability: Ownership structure has remained relatively stable with no major reported changes in recent years, supporting continuity in strategy and operations.

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS): Ownership Structure

• Mission and Values: Improve global health by providing safe, effective medications through innovation and scientific expertise; emphasize integrity, ethics and stakeholder trust.
• Sustainability: Active initiatives to reduce carbon footprint and promote environmental responsibility across manufacturing and supply chains.
• R&D Commitment: Allocates approximately 10% of annual revenue to research and development for new drugs and improved formulations.
• Collaboration: Pursues strategic partnerships with hospitals, research institutes and multinational pharma companies to broaden pipeline and market access.
• Customer-centricity: Focuses on patient and healthcare-professional needs across product development, quality and distribution.

• Product mix: Revenue stems from prescription drugs (including TCM formulations), OTC consumer health products, and contract manufacturing/licensing.
• Sales channels: Domestic hospital procurement, retail pharmacy chains, e-commerce platforms and exports to select international markets.
• Value drivers: New drug launches, label expansions for legacy products, cost control in large-scale production, and margin management in OTC vs hospital sales.

• Major shareholders typically include state-owned or industry-related institutional investors, management/insiders and public float on the Shanghai Stock Exchange (ticker: 600750.SS).
• Corporate governance emphasizes compliance with Chinese regulatory standards for listed pharmaceutical firms and disclosure of R&D pipelines, clinical progress and manufacturing quality controls.

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS): Mission and Values

• Management and governance: centralized management structure with a board of directors and senior executives overseeing R&D, manufacturing, sales & marketing, regulatory affairs and finance.
• R&D focus: a robust R&D division driving new formulations, quality improvement and clinical research; the company reinvests approximately 10% of annual revenue back into R&D activities.
• Manufacturing: multiple GMP-certified production sites equipped with advanced production lines (many imported from developed countries) to ensure consistent product quality and scale.
• Distribution: a nationwide distribution network partnering with over 5,000 pharmacies across China to secure wide product availability.
• E-commerce and omni-channel sales: significant digital channel presence-online sales accounted for roughly 25% of total revenue in 2022, supported by Tmall, JD and company-owned e-commerce stores.
• Quality and certifications: ISO9001, ISO14001, OHSAS18001 and recognition as a nationally certified GMP enterprise; rigorous QC labs and batch-release testing protocols.

• Primary revenue streams:
  • Prescription and over-the-counter (OTC) pharmaceuticals (both TCM and chemical medicines)
  • Health supplements and consumer healthcare products
  • Online retail and platform sales
  • Institutional sales to hospitals and distributors
• Profitability drivers: product mix (higher-margin OTC/consumer goods vs. institutional sales), scale in manufacturing, cost controls in procurement and logistics, and premium pricing for proprietary formulations.

• Facilities: multiple plants with automated filling, coating and packaging lines; key equipment sourced from Europe, North America and Japan to meet high throughput and sanitary standards.
• QC regimes: raw material testing, in-process controls, stability studies and finished-product release; environmental and occupational health systems consistent with ISO14001 and OHSAS18001.
• Regulatory compliance: national GMP certification for core facilities and periodic regulatory inspections for clinical and manufacturing activities.

• Retail network: direct partnerships and distribution agreements covering over 5,000 pharmacies, community drugstores and hospital pharmacies across provinces.
• E-commerce strategy: presence on major platforms complemented by brand stores and digital marketing; estimated 25% of 2022 revenue generated online.
• Institutional and tender sales: participation in regional procurement and hospital tenders for larger-volume contracts.

• Revenue generation: sales of finished pharmaceuticals and health products through retail, online and institutional channels.
• Investment priorities: sustained R&D investment (~10% of revenue), capacity upgrades in manufacturing, and digital channel expansion.
• Cost structure: raw materials and active pharmaceutical ingredients (APIs), production overhead, sales & marketing (including distributor margins), and regulatory/compliance expenses.
• Margin levers: higher-margin OTC/consumer brands, economies of scale in manufacturing, and premium pricing for proprietary or clinically-differentiated products.

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS): How It Works

• OTC product sales - core branded items such as stomach-strengthening tablets and multivitamin tablets sold through pharmacies, supermarkets and e-commerce.
• Health consumer products - gastrointestinal and liver health supplements positioned for long-term consumer use, often cross-sold with OTC items.
• Prescription medicines - traditional Chinese medicine (TCM) prescriptions and chemical drugs sold to hospitals and clinic channels; sizable margin and volume contribution.
• Medicinal materials trading - sourcing, processing and sales of raw materials (e.g., stir-fried Chinese jujube seeds, French pinellia) to internal production lines and third parties.
• E-commerce and digital channels - company-owned stores and third-party platforms contributing an increasing share of total sales.
• Contract manufacturing and licensing - production services for other healthcare brands and licensing revenue for proprietary formulations.

• Branded OTC portfolio with stable gross margins and recurring consumer demand.
• Higher-margin prescription portfolio supported by formulary listings and hospital relationships.
• Vertical integration of medicinal materials to control input costs and ensure supply stability.
• Investment in digital marketing and logistics to scale e-commerce sales-online share has risen materially in recent years.
• Scale manufacturing and occasional contract production to improve capacity utilization and spread fixed costs.

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS): How It Makes Money

• Market capitalization: ~15.29 billion yuan (as of 15 Dec 2025)
• Trailing P/E: 16.92; Forward P/E: 17.47 - signaling stable investor confidence
• H1 2025 net profit: ~522 million yuan, up 5.8% YoY

• Publicly traded on SSE (600750.SS) with institutional and retail investor mix.
• Board and management emphasize R&D spending and portfolio diversification to drive mid-term growth.

• Mission: develop safe, effective pharmaceuticals combining modern science and TCM heritage.
• Strategic priorities: R&D acceleration, product diversification, sustainability, and ethical manufacturing.

• R&D investment to expand patented TCM-derived and modern drug portfolios.
• Geographic expansion and deeper penetration of retail pharmacy and hospital channels.
• Sustainability and ethical practice initiatives to strengthen brand and meet regulatory/consumer expectations.
• Cost control and margin optimization through manufacturing efficiency.